COPB2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10608(COPB2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P10608(COPB2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The COPB2 antibody targets the Coatomer Protein Complex Subunit Beta 2 (COPB2), a critical component of the COPI (coatomer protein complex I) vesicle complex involved in intracellular transport. COPI mediates retrograde trafficking of proteins and lipids from the Golgi apparatus to the endoplasmic reticulum, ensuring proper protein sorting, organelle maintenance, and cellular homeostasis. COPB2. as one of seven subunits in the COPI complex, plays a role in stabilizing the coatomer structure and facilitating vesicle formation.

Antibodies against COPB2 are widely used in research to study its expression, localization, and functional roles in cellular processes. They are applied in techniques like Western blotting, immunofluorescence, and immunoprecipitation to investigate COPI-dependent trafficking mechanisms. Dysregulation of COPB2 has been linked to diseases, including cancers, where its overexpression correlates with tumor progression, metastasis, and poor prognosis, possibly due to disrupted protein transport and signaling pathways.

Recent studies also explore COPB2's involvement in neurodegenerative disorders and viral infections, where COPI dysfunction may impair host cell defenses. Researchers utilize COPB2 antibodies to validate gene-editing outcomes (e.g., CRISPR) or assess therapeutic targeting in preclinical models. However, specificity validation (e.g., knockout controls) is essential to avoid off-target artifacts. Overall, COPB2 antibodies serve as key tools for unraveling vesicular trafficking biology and its implications in health and disease.